ATRC Quote, Financials, Valuation and Earnings

Alphatec Holdings, Inc. has a net margin of -0.2% compared to AtriCure, Inc.'s net margin of -14.54%. AtriCure, Inc.'s return on equity of -6.2% beat Alphatec Holdings, Inc.'s return on equity of -1495.13%.

AtriCure, Inc. has a consensus price target of $52.78, signalling upside risk potential of 42.22%. On the other hand Alphatec Holdings, Inc. has an analysts' consensus of $24.62 which suggests that it could grow by 78.11%. Given that Alphatec Holdings, Inc. has higher upside potential than AtriCure, Inc., analysts believe Alphatec Holdings, Inc. is more attractive than AtriCure, Inc..

AtriCure, Inc. has a beta of 1.415, which suggesting that the stock is 41.514% more volatile than S&P 500. In comparison Alphatec Holdings, Inc. has a beta of 1.013, suggesting its more volatile than the S&P 500 by 1.34%.

AtriCure, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alphatec Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AtriCure, Inc. pays -- of its earnings as a dividend. Alphatec Holdings, Inc. pays out -- of its earnings as a dividend.

AtriCure, Inc. quarterly revenues are $134.3M, which are smaller than Alphatec Holdings, Inc. quarterly revenues of $196.5M. AtriCure, Inc.'s net income of -$267K is higher than Alphatec Holdings, Inc.'s net income of -$28.6M. Notably, AtriCure, Inc.'s price-to-earnings ratio is -- while Alphatec Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AtriCure, Inc. is 3.40x versus 2.81x for Alphatec Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Boston Scientific Corp. has a net margin of -0.2% compared to AtriCure, Inc.'s net margin of 12.68%. AtriCure, Inc.'s return on equity of -6.2% beat Boston Scientific Corp.'s return on equity of 12.46%.

AtriCure, Inc. has a consensus price target of $52.78, signalling upside risk potential of 42.22%. On the other hand Boston Scientific Corp. has an analysts' consensus of $106.78 which suggests that it could grow by 40%. Given that AtriCure, Inc. has higher upside potential than Boston Scientific Corp., analysts believe AtriCure, Inc. is more attractive than Boston Scientific Corp..

AtriCure, Inc. has a beta of 1.415, which suggesting that the stock is 41.514% more volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.666, suggesting its less volatile than the S&P 500 by 33.441%.

AtriCure, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AtriCure, Inc. pays -- of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend.

AtriCure, Inc. quarterly revenues are $134.3M, which are smaller than Boston Scientific Corp. quarterly revenues of $5.3B. AtriCure, Inc.'s net income of -$267K is lower than Boston Scientific Corp.'s net income of $670M. Notably, AtriCure, Inc.'s price-to-earnings ratio is -- while Boston Scientific Corp.'s PE ratio is 39.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AtriCure, Inc. is 3.40x versus 5.68x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.

iRhythm Holdings, Inc. has a net margin of -0.2% compared to AtriCure, Inc.'s net margin of -2.7%. AtriCure, Inc.'s return on equity of -6.2% beat iRhythm Holdings, Inc.'s return on equity of -54.18%.

AtriCure, Inc. has a consensus price target of $52.78, signalling upside risk potential of 42.22%. On the other hand iRhythm Holdings, Inc. has an analysts' consensus of $221.27 which suggests that it could grow by 51.07%. Given that iRhythm Holdings, Inc. has higher upside potential than AtriCure, Inc., analysts believe iRhythm Holdings, Inc. is more attractive than AtriCure, Inc..

AtriCure, Inc. has a beta of 1.415, which suggesting that the stock is 41.514% more volatile than S&P 500. In comparison iRhythm Holdings, Inc. has a beta of 1.062, suggesting its more volatile than the S&P 500 by 6.245%.

AtriCure, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iRhythm Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AtriCure, Inc. pays -- of its earnings as a dividend. iRhythm Holdings, Inc. pays out -- of its earnings as a dividend.

AtriCure, Inc. quarterly revenues are $134.3M, which are smaller than iRhythm Holdings, Inc. quarterly revenues of $192.9M. AtriCure, Inc.'s net income of -$267K is higher than iRhythm Holdings, Inc.'s net income of -$5.2M. Notably, AtriCure, Inc.'s price-to-earnings ratio is -- while iRhythm Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AtriCure, Inc. is 3.40x versus 6.62x for iRhythm Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics, Inc. has a net margin of -0.2% compared to AtriCure, Inc.'s net margin of -316.61%. AtriCure, Inc.'s return on equity of -6.2% beat Plus Therapeutics, Inc.'s return on equity of --.

AtriCure, Inc. has a consensus price target of $52.78, signalling upside risk potential of 42.22%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 2016.2%. Given that Plus Therapeutics, Inc. has higher upside potential than AtriCure, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than AtriCure, Inc..

AtriCure, Inc. has a beta of 1.415, which suggesting that the stock is 41.514% more volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.364%.

AtriCure, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AtriCure, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.

AtriCure, Inc. quarterly revenues are $134.3M, which are larger than Plus Therapeutics, Inc. quarterly revenues of $1.4M. AtriCure, Inc.'s net income of -$267K is higher than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, AtriCure, Inc.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AtriCure, Inc. is 3.40x versus 4.17x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.